Form 8-K TG THERAPEUTICS, INC. For: Nov 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TG Therapeutics' (TGTX) Q3 Results Solid; Roth Remains Positive into ASH Conference
November 9, 2015 2:20 PM ESTRoth Capital affirmed its Focus Pick rating and $33 price target on TG Therapeutics (NASDAQ: TGTX) following the company's Q3 report and update issued earlier Monday.
Analyst Joseph Pantginis commented, We believe that TG is entering an intriguing time as we look toward more mature data updates at ASH... More
TG Therapeutics (TGTX) Tops Q3 EPS by 6c
November 9, 2015 7:49 AM ESTTG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of ($0.28), $0.06 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $38.1 thousand versus the consensus estimate of $40 thousand.
For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.
... More